Senate Health and Human Services Committee
Sophie Walsh 271-3469
SB 17-FN, relative to insurance cost-sharing calculations.
Hearing Date: January 15, 2025
Time Opened: 9:38 a.m. Time Closed: 10:58 a.m.
Members of the Committee Present: Senators Rochefort, Avard, Birdsell, Prentiss and Long
Members of the Committee Absent : None
Bill Analysis: This bill provides that, when calculating an enrollee's contribution to cost-sharing requirements, the insurer or pharmacy benefits manager shall include any amount paid by the enrollee or paid on their behalf. The bill includes a limited exception for health savings account-qualified high deductible health plans if application of the requirement would result in account ineligibility under the Internal Revenue Code.
Sponsors:
Sen. Innis |
|
|
________________________________________________________________________________
Who supports the bill: Sen. Innis, Mike Rollo (American Cancer Society Cancer Action Network), Susanna von Oettingen, Amanda Attiya (Cystic Fibrosis Foundation), and Kathryn Morgan.
Who opposes the bill: Paula Rogers (AHIP), Lindsay Nadeau (Cigna), Cam Lapine (Cigna), Curtis J. Barry (Pharmaceutical Care Management Association), Sam Hallemeier (Pharmaceutical Care Management Association), Sabrina Dunlap (Anthem), and Peter Bragdon (Harvard-Pilgrim).
Who is neutral on the bill: No one.
Summary of testimony presented:
Senator Dan Innis, Senate District 7
- Senator Innis introduced SB 17, which passed through the Senate 24-0 last year.
- This bill is an effort to improve affordability and reduce out-of-pocket patient expenses.
- The need for co-pay assistance for prescription medication is critical for people with high deductible health insurance plans.
- Co-pay assistance is real money; it is not a discount or coupon, nor is it a way to steer patients towards branded medication.
- Senator Innis explained that co-pay accumulators and maximizer programs allow private insurance companies and pharmacy benefit managers (PBMs) to reap significant profits while patients are forced to abandon or delay treatment due to high out-of-pocket costs.
- An increasing number of insurance plans and PBMs have begun implementing cost-shifting tactics, such as accumulators and maximizers. These programs bar third party-provided co-pay from counting towards a patient’s deductible or out-of-pocket maximum.
- This exposes patients to large and unexpected costs, interrupts treatment regimens, and undermines patient protection. Senator Innis said he has seen this happen with his sister in another state, where she had to suspend treatment for two months.
- An estimated 310,000 patients in New Hampshire would be affected by this program if implemented.
- 99.6% of co-pay assistance is used for branded drugs with no generic alternatives.
- A recent American Cancer Society survey of cancer patients and their caregivers found that 83% of respondents felt that manufacturer assistance programs enabled them to get medication they otherwise could not afford.
- Senator Innis stated that this bill would put an end to insurer double-dipping and ensure that patients get the full benefit of co-pay assistance and have it count toward their deductibles.
- Senator Avard asked how this will affect insurance rates.
- Senator Innis said the committee may hear that insurance rates will increase substantially as a result and acknowledged that there could be some impact. He emphasized that any increase should not be significant, but the benefits to individuals will be.
Susanna von Oettingen
- Ms. von Oettingen introduced herself as a New Hampshire State Lead for the New England Bleeding Disorders Advocacy Coalition. She is also the mother of a 27-year-old son with severe hemophilia.
- She believes copay accumulator adjustment programs are detrimental to patients by increasing their medical expenses and drug costs. This could possibly lead to decisions to not take costly life-saving medications to save money, possibly resulting in increased medical costs due to more severe illness.
- Last year when her son turned 26, their family looked at the state insurance marketplace. After speaking with two insurers, they were able to ascertain that one of them did use copay accumulator adjustments; while the agent did not explicitly admit it, they did clearly indicate it. The other insurer never responded to their inquiry.
- Ms. von Oettingen explained that her son’s monthly salary is barely sufficient to cover living and medical expenses. It is likely that if he must decide between paying bills or his monthly co-pay, he will try to stretch out his medication to make it last longer. This could have dangerous consequences.
- Ms. von Oettingen’s son’s medication must be purchased at a specialty pharmacy, as it is not available in general pharmacies or most hospitals.
- Ms. von Oettingen referenced the methodology section of SB 17 and explained that a 2023 analysis of the annual rate of insurance premium increases indicated that insurance rates have not been affected in 19 states, D.C., and Puerto Rico.
- Ms. von Oettingen questioned how the Insurance Department concluded that premiums would rise because she has found no supporting documentation in published literature.
- Ms. von Oettingen again referenced the methodology section of SB 17, saying that her understanding is that insurers are increasing the expenses of chronically ill patients relying on non-generic, specialty medications, so that the economics of cost estimation are not disrupted.
- Senator Rochefort asked if the specialty pharmacy they use is owned by the insurance company or PBM.
- Ms. von Oettingen explained that it is associated with their hemophilia treatment center, but she has heard of specialty pharmacies being owned by pharmaceutical stores like CVS.
Paula Rogers, America’s Health Insurance Plans (AHIP)
- Ms. Rogers explained that this is essentially last year’s bill with one change, basically mandating that manufacturer-provided coupons be registered for their value in a member’s deductible.
- Ms. Rogers recalled that last year, patient advocates expressed struggle at point of sale with expensive medications.
- Ms. Rogers pointed out that the perspective of manufacturers has been missing from the conversation, and that we need to hear from them about the costs of medications.
- Ms. Rogers referenced the fiscal note of SB 17 and explained that co-pays, deductibles, and the like are a reality of our marketplace to make products affordable.
- This bill does not cover Medicare, Medicaid, self-insured programs, or the state employee program. While this only covers a narrow area of the marketplace, the marketplace is always sensitive to premium pressure.
- Ms. Rogers advised caution before passing this bill and pointed out that it covers more than pharmaceuticals in its current form.
- Last session, SB 354 was amended in the House to: clearly limit the scope of the co-pay issue to prescription drugs, recognize independent charity assistance programs, and require that assistance from those programs be included when the member’s cost-share is calculated and accumulated.
- Another resulting issue is that coupons are only helpful to members on a short-term basis. This is problematic from a patient-protection point of view.
- Ms. Rogers recalled that Senator Bradley felt the amended bill to be not as generous as the Senate version in last year’s SB 354 Committee of Conference. She sees the amended version as a more careful bill focusing on independent charity participation and on a group that is most burdened with cost challenges at point of sale.
- While AHIP opposes the bill in its present form, they worked on last year’s House amendment and would like to continue working in that direction.
- Senator Avard asked if this would put any pressure on manufacturers to lower costs.
- Ms. Rogers said this will put pressure on premiums for health carriers.
- She emphasized that upon her review of last year's hearing report, no pharmaceutical manufacturers seemed to be present. While there are some community benefits, it is a marketing tool.
- Furthermore, some physicians feel as though patients decide what medication they need before they have received a diagnosis due to advertising.
- She expressed hope that manufacturers will answer some of these questions, as drug prices are a federal problem.
- Senator Rochefort asked if PBMs play a role in determining high-cost drug prices.
- Ms. Rogers said she assumes pressure is coming from many directions, and that transparency is needed. She acknowledged that PBMs get paid by health plans.
- Senator Rochefort asked what the difference is between using a coupon and paying for a neighbor’s co-pay.
- Ms. Rogers explained the difference is that the manufacturer providing the coupon is a for-profit business entity.
- She suggested asking what happens to co-pay money when it is collected at point of sale and where exactly it goes.
Curtis J. Barry and Sam Hallemeier, Pharmaceutical Care Management Association (PCMA)
- Mr. Barry answered Senator Rochefort’s previous question, explaining that there is an important distinction between cash assistance provided by a charity, relative, or church and a manufacturer coupon.
- While those providing cash assistance likely do not have a stake in what drug their contribution pays for, manufacturer coupons are for a specific drug.
- He explained there are a lot of lower-cost drugs, such as branded biologics and branded alternatives, that should be considered.
- Mr. Hallemeier stated that they are speaking in opposition to the bill.
- Their main concern is that this will steer patients towards more expensive drugs and therapies under the guise of a lower co-pay.
- They are concerned that this will ultimately raise premiums for everyone on the plan, while only a few would receive the lower co-pay.
- These coupons are banned in government programs like Medicare and Medicaid, as they are considered kickbacks.
- Mr. Hallemeier presented research and statistics they have gathered. They have found that: co-pay coupon list prices are increasing faster than drugs without a co-pay coupon, if coupons were allowed in Medicare it would result in a $48 billion increase over ten years, and there is a 20:1 return in profits for manufacturers.
- Rather than lowering the list-prices of these medications, manufacturers have found that using co-pay coupons to steer patients towards more expensive drugs will increase their profits and insurance premiums.
- Mr. Barry questioned why this is not being extending to the state employee plan if it is good policy.
- He also questioned why name-brand drugs are expensive, and referenced a handout submitted to the committee that reviewed name-brand drugs and their patents. He emphasized that the increase in drug prices is starting with manufacturers.
- Mr. Barry referenced a study submitted to the committee demonstrating how implementing this concept in Medicare would raise costs.
- Mr. Barry presented a chart describing the profit margins of the players in the drug reimbursement distribution system.
- Mr. Barry referenced an AARP study, showing the cost of therapy per drug and cost of therapy per drug if prices were limited to inflation.
- Senator Rochefort asked if PBMs are collecting any fee, recoupment, or rebate on the coupons that are used. Mr. Hallemeier said he is not aware of that happening now.
- Senator Long asked if they agreed that the figure of 310,000 patients being affected in NH proposed earlier is accurate.
- Mr. Barry said it sounds high to him, and that it may just be the total number of people in the fully insured market and not necessarily the amount of people who receive coupon assistance.
- Senator Long asked if enrollees still benefit with rising premiums.
- Mr. Barry explained that the few people receiving coupon assistance will benefit, but emphasized that the issue at question relative to this bill is if that coupon should be applicable to the deductible. Coupons are not prohibited currently.
- Senator Rochefort asked, given there is no clinical advantage to a drug and it is simply a price issue, if it is the responsibility of the PBM to say no.
- Mr. Hallemeier explained that PBMs do not set co-pays, but they do work with plans to design their benefit. In regard to the formulary, PBMs will pit manufacturers against one another to get a lower net price. However, manufacturers can still offer coupons on top of that. Mr. Hallemeier emphasized that manufacturers should just lower their prices.
Peter Bragdon, Harvard-Pilgrim
- Mr. Bragdon stated that he is opposed to this bill, but he would be happy to work on it.
- These programs, in many cases, are schemes by drug companies to shift away patients to much more expensive drugs
- Mr. Bragdon knows of no insurance company that would have any problem with friends, families, or churches providing contributions for an individual’s co-pay.
- Mr. Bragdon provided an example to demonstrate how insurance carriers absorb the cost of name-brand drugs in these situations. If a patient opts to use a more expensive drug because they have a coupon, when their deductible eventually is reached and the coupon expires, the insurance carrier will continue having to pay the full price of that medication.
- Mr. Bragdon read an excerpt written by Prescription Drug Affordability Board, explaining that these programs can actually undermine cost-containment efforts.
- Insurance carriers have very few tools in terms of prescription drug prices, and their biggest tool is the formulary.
- In the big picture, higher pressure on premiums is something to be avoided for the overall good of the market and individuals in the market.
- Mr. Bragdon said it may be worth investigating the difference between generics, biosimilars, and branded alternatives.
- His understanding is that 88% of the drugs coupons are used for do have a generic, biosimilar, or alternative branded drug. In 12% of situations there is no alternative. These are the situations they want to find solutions for, but they do not want to undermine the overall structure of prescription drug benefits.
- Mr. Bragdon cited a 2017 study comparing Massachusetts (which does not allow coupons) and New Hampshire. It found that the use of generic drugs in New Hampshire declined, and that spending on brand prescription drugs increased by 60%.
- Mr. Bragdon emphasized that if there is no cost to this, it would be extended to the state employee plan.
- Senator Avard inquired about tracking coupons and using a brand-name drug until the coupon expires and then switching to a generic.
- Mr. Bragdon explained that there would be no incentive for the consumer to switch, as it would not cost them anything at that point. He also noted that switching treatment is probably not recommended. He said this is why formularies exist, to offer lower prices on the medications they want to encourage.
- Senator Birdsell asked for Mr. Bragdon’s perspective on amending the bill to address conditions that have no alternatives and require brand-name drugs.
- Mr. Bragdon said that he would be very open to that conversation, as their overall concern is how this could be used to subvert the formulary.
Sabrina Dunlap, Anthem
- Ms. Dunlap said she is opposed to the bill as written.
- She thinks the amendments from last year are worth revisiting.
- She agreed with Ms. Rogers’ previous comment, explaining that drug manufacturers need to be a part of the discussion because they are setting drug prices and offering coupons to create an allusion of affordability.
- Ms. Dunlap emphasized that the federal government considers these coupon programs to be an illegal kickback.
- Anthem and other carriers have developed programs to help reduce out-of-pocket costs for members with high-cost specialty drugs. This would interfere with their ability to administer that program.
- Ms. Dunlap has a child in the rare and chronic disease space, so she is familiar with specialty drugs and the programs offered by drug manufacturers.
- Anthem wants their members to have access to these drugs, but they do not think this will ultimately help with the affordability of those drugs.
- There is not a lot of consumer protection from manufacturers for those signed up for coupon programs.
- Ms. Dunlap said Anthem is willing to participate in discussions about potential amendments.
- Senator Avard asked how these programs are available if they are essentially illegal federally.
- Ms. Dunlap clarified that the federal government considers certain co-pay coupon programs to be an illegal kickback, so they are not permitted under Medicare or Medicaid. They are permitted in the commercial space.
Mike Rollo, American Cancer Society Cancer Action Network (ACSCAN)
- Mr. Rollo stated that ACSCAN is in full support of this bill, as they were last year.
- Many cancer patients have difficulty affording the cost of prescription drugs. This is especially true for newer drugs that do not yet have generic equivalents.
- Manufacturer programs and charitable patient assistance programs help many cancer patients afford their medications.
- Co-pay accumulators are a relatively new insurance benefit design that allows enrollees to use co-pay support, but it does not count towards the deductible or out-of-pocket maximum.
- This bill is not a coverage mandate, and it does not require insurance companies to cover any particular drug or class of drugs.
- Mr. Rollo said that ACSCAN is fine with including biologics and biosimilars.
- The Pioneer Foundation, the AIDS Institute, and the Global Healthy Foundation all found in three separate studies that these policies will not have a negative impact or raise premiums.
- Mr. Rollo explained that the amendment from the House would have precluded a majority of charitable support.
- Mr. Rollo personally knows a lot of people who have or have had cancer, and none of them ever requested a more expensive drug from their doctor simply because they found a coupon.
Peter Bragdon, Harvard-Pilgrim
- Mr. Bragdon clarified that the Global Healthy Living Foundation has twenty-five listed corporate partners, twenty-three of which are drug companies.
SW
Date Hearing Report completed: January 21, 2025